Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Prepaid Assets: 2011-2025

Historic Prepaid Assets for Adma Biologics (ADMA) over the last 10 years, with Sep 2025 value amounting to $6.9 million.

  • Adma Biologics' Prepaid Assets fell 27.40% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year decrease of 27.40%. This contributed to the annual value of $8.0 million for FY2024, which is 50.52% up from last year.
  • Latest data reveals that Adma Biologics reported Prepaid Assets of $6.9 million as of Q3 2025, which was down 14.32% from $8.1 million recorded in Q2 2025.
  • Adma Biologics' Prepaid Assets' 5-year high stood at $9.5 million during Q3 2024, with a 5-year trough of $3.7 million in Q1 2024.
  • In the last 3 years, Adma Biologics' Prepaid Assets had a median value of $5.5 million in 2024 and averaged $6.4 million.
  • Over the last 5 years, Adma Biologics' Prepaid Assets had its largest YoY gain of 129.59% in 2025, and its largest YoY loss of 27.40% in 2025.
  • Quarterly analysis of 5 years shows Adma Biologics' Prepaid Assets stood at $4.3 million in 2021, then climbed by 17.42% to $5.1 million in 2022, then climbed by 4.69% to $5.3 million in 2023, then soared by 50.52% to $8.0 million in 2024, then fell by 27.40% to $6.9 million in 2025.
  • Its last three reported values are $6.9 million in Q3 2025, $8.1 million for Q2 2025, and $8.6 million during Q1 2025.